

Stock Idea Note - Emami Ltd

Company Overview

Emami operates primarily in beauty and healthcare, offering more than 550 products across categories such as skin care, hair care, pain management balms, cooling oils, and over-the-counter healthcare remedies. Its portfolio includes power brands like Navratna cooling oil, BoroPlus antiseptic cream, Zandu Balm, Mentho Plus, Kesh King hair oil, and Smart & Handsome (earlier Fair & Handsome) men’s grooming range, many of which enjoy leadership positions in their respective niches. The company generated around Rs. 3,800+ crores in turnover in FY25, positioning it among India’s larger listed FMCG companies by revenue. Emami’s products are available through a wide distribution network spanning over 5.4 million retail outlets in India serviced by more than 3,400 distributors, and a global footprint in 70+ countries across SAARC, Middle East, Africa, CIS, and parts of Europe and Southeast Asia. A key pillar of Emami’s strategy is continuous brand-building and innovation in ayurvedic and natural propositions that resonate strongly with Indian consumers. The company regularly launches new products and extensions (over 25 launches in FY25 alone) and undertakes periodic rebranding and relaunches, such as rebranding Fair & Handsome to Smart & Handsome, to keep core brands contemporary and align with evolving consumer preferences. Emami has complemented organic growth with a series of acquisitions to enter new categories and geographies, including the acquisition of Zandu in 2008, Kesh King in 2015, German skincare brand Creme 21 in 2019, and Dermicool prickly heat talc in 2022. More recently, it has invested in digital-first and niche brands (such as male grooming, health beverages, skincare, and pet care) to build future growth engines and strengthen its presence in modern trade, e-commerce, and direct-to-consumer channels.

Investment Rationale

Business performance to be aided by margin expansion tailwinds and operational leverage

The company has systematically pursued initiatives to expand margins beyond commodity price cycles. Firstly, product premiumization which includes shifting the sales mix toward higher-margin variants and premium sub-brands like Smart & Handsome (men’s grooming premium positioning) and Brillare (professional skincare) has helped in creating pricing power that exceeds cost inflation. Secondly, operational efficiency initiatives such as manufacturing optimization, distribution route optimization, and digital transformation in supply chain are expected to yield improvement in margins. Thirdly, increased advertising and promotional spending remains disciplined, with the company strategically allocating spends to revitalize under-performing brands (e.g., Kesh King relaunch, Smart & Handsome portfolio expansion) rather than indiscriminate mass-market campaigns. This focused approach maximizes return on marketing investment and drives volume-led rather than discount-led growth.

Diversified brands, market leadership in key categories and cooling commodity prices provides headroom for growth

Emami Ltd. has established a robust leadership position in the FMCG landscape, backed by a diversified portfolio of 550+ products across personal care, healthcare, and lifestyle categories. Its powerhouse brands anchor strong pricing power, deep consumer loyalty, and superior operating leverage. BoroPlus dominates the antiseptic cream market with a 67.7% share, Navratna Cool Oil leads the medicated cooling oil segment at 62.8%, Kesh King holds 29.4% of the ayurvedic hair care market, and Dermicool commands 14% in prickly heat powders, collectively reinforcing Emami’s competitive moat. These entrenched positions translate into stable, high-margin revenue streams and strong resilience against competitive intensity. While seasonal categories such as prickly heat and talc face demand volatility, Emami’s healthcare portfolio, spanning pain relief, digestive care, and functional beverages, delivers more consistent performance, supported by long-term health and wellness trends. With raw material prices like copra and palm oil continuing to soften, the company is well positioned to capture meaningful margin tailwinds. This combination of strong category leadership, a balanced portfolio mix, and easing input costs enhances Emami’s profitability outlook and strengthens its long-term growth trajectory.

Stock Rating

BUY	HOLD	SELL
> 15%	-5% to 15%	< -5%

Sector Outlook

Positive

Stock

CMP (INR)	530
Target Price (INR)	613
NSE Symbol	EMAMILTD
BSE Code	531162
Bloomberg	HMN IN
Reuters	EMAM.BO


Key Data

Nifty	26,203
52WeekH/L(Rs.)	690/498
O/s Shares (Cr.)	43.7
Market Cap (Rs, Cr.)	23032
Face Value (Rs.)	1


Average volume

3 months	6,27,175
6 months	6,87,240
1 year	6,50,300

Share Holding Pattern (%)



Relative Price Chart



Stock Idea Note - Emami Ltd

Valuation and Outlook

Emami Ltd. stands out as a structurally attractive FMCG play with sustainable medium-term growth prospects, underpinned by core brand strength, consistent innovation, and operational discipline. Key triggers, such as new products, channel evolution, inorganic ventures, and cost management strategies, are expected to drive high double-digit revenue and earnings growth, with improving margins and return ratios. Despite external risks, Emami's robust balance sheet, agile strategy, and favourable consumption trends lend strong support to its investment appeal. At current valuations, the stock appears attractive, particularly as softening palm oil and copra prices are likely to aid margin expansion. The company's operating profit margin (OPM) stands at approximately 26–27% range, benefiting from favorable gross margins driven by moderating raw material costs (particularly crude oil derivatives, which directly impact balms, creams, and hair oils). Management guidance suggests sustained EBITDA margins in the 26–27% range through FY26–FY27, reflecting operational stability despite near-term macroeconomic headwinds. Coupled with healthy topline momentum and a rising share of high-margin categories, the long-term outlook remains strong. So, valuing the company at 28x FY26e earnings, we arrive at a target price of Rs. 613, implying a 16% potential upside over a 12-month horizon.

Key Financials						
YE March (INR. Mn)	FY22	FY23	FY24	FY25	FY26E	FY27E
Revenue	3,187	3,406	3,578	3,809	4,152	4,546
Revenue Growth (Y-o-Y)	-	6.9%	5.1%	6.5%	9.0%	9.5%
EBITDA	952	863	950	1,025	1,138	1,261
EBIT Growth (Y-o-Y)	-	(9.4%)	10.1%	8.0%	11.0%	10.8%
Net Profit	837	627	724	803	955	1,118
Net Profit Growth (Y-o-Y)	-	(25.0%)	15.4%	10.9%	19.0%	17.0%
Diluted EPS	18.9	14.5	16.6	18.5	21.9	25.6
Diluted EPS Growth (Y-o-Y)	-	176.5%	29.8%	41.0%	37.7%	18.7%
Key Ratios						
EBITDA margin (%)	29.9%	25.3%	26.5%	26.9%	27.4%	27.7%
NPM (%)	26.3%	18.4%	20.2%	21.1%	23.0%	24.6%
RoE (%)	40.3%	27.1%	29.5%	29.8%	31.0%	31.9%
RoCE (%)	26.2%	25.6%	29.9%	30.4%	31.2%	31.3%
Valuation Ratios						
P/E (x)	28.1x	36.6x	32.1x	28.7x	24.2x	20.7x
EV/EBITDA (x)	24.6x	26.9x	24.4x	22.6x	20.3x	18.3x
P/BV (x)	11.2x	10.0x	9.4x	8.6x	7.5x	6.6x
Market Cap. / Sales (x)	7.3x	6.8x	6.5x	6.1x	5.6x	5.1x

Source: Bloomberg, BP Equities Research



BP WEALTH

Tel: +91 22 61596138

Research Desk

Institutional Sales Desk

Tel: +91 22 61596403/04/05

Disclaimer Appendix**Analyst (s) holding in the Stock : Nil****Analyst (s) Certification:**

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

General Disclaimer

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Corporate Office:

4th floor,
Rustom Bldg,
29, Veer Nariman Road, Fort,
Mumbai-400001
Phone- +91 22 6159 6464
Fax-+91 22 6159 6160
Website- www.bpwealth.com

Registered Office:

24/26, 1st Floor, Cama Building,
Dalal street, Fort,
Mumbai-400001

BP Wealth Management Pvt. Ltd.
CIN No: U67190MH2005PTC154591

BP Equities Pvt. Ltd.
CIN No: U67120MH1997PTC107392